Christopher Peetz, an officer and director of Mirum Pharmaceuticals, Inc., filed a Form 144 notice of proposed sale of 20,000 shares of common stock, dated November 20, 2026.

Key Highlights

  • Proposed sale: Christopher Peetz intends to sell 20,000 shares of Mirum Pharmaceuticals common stock with an aggregate market value of $1,940,100.00.
  • Acquisition method: The 20,000 shares were acquired on November 20, 2026, via stock options exercise from the issuer, with payment made in cash.
  • Broker named: The proposed sale is to be executed through Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.
  • Shares outstanding: According to the filing, 65,282,044 shares of common stock were outstanding at the time of notice.
  • Prior sales in past 3 months: Peetz sold 20,000 shares on November 4, 2026, for gross proceeds of $1,800,000.00, and 30,000 shares on September 1, 2026, for gross proceeds of $2,960,319.00.
  • Rule 10b5-1 plan: The filing indicates a trading plan adoption date of March 2, 2026.

Peetz Form 144 Notice: Stock Options Exercise and Proposed Sale Details

According to the Form 144 filing submitted on November 20, 2026, Christopher James Peetz, identified as both an officer and director of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), provided notice of a proposed sale of 20,000 shares of the company's common stock. The aggregate market value of the shares to be sold was listed as $1,940,100.00. The proposed sale is to be conducted on the NASDAQ exchange through Morgan Stanley Smith Barney LLC Executive Financial Services.

The filing discloses that the 20,000 shares subject to this proposed sale were acquired on November 20, 2026, through a stock options exercise from the issuer, with full cash payment made on the same date. The filing also notes that Peetz is relying on Rule 10b5-1, with a plan adoption date of March 2, 2026. By signing the notice, the filer represented, as of the plan adoption date, that he did not know of any material adverse information regarding the current and prospective operations of Mirum Pharmaceuticals that had not been publicly disclosed.

The filing further reports that within the three months preceding this notice, Peetz sold 20,000 shares of common stock on November 4, 2026, generating gross proceeds of $1,800,000.00, and 30,000 shares on September 1, 2026, generating gross proceeds of $2,960,319.00. The issuer's address is listed as 989 East Hillsdale Boulevard, Suite 300, Foster City, California 94404, with SEC File Number 001-38981.

What Was Disclosed

Mirum Pharmaceuticals officer and director Christopher Peetz filed a Form 144 notice on November 20, 2026, disclosing a proposed sale of 20,000 common shares valued at $1,940,100.00, acquired via stock options exercise, under a Rule 10b5-1 plan adopted March 2, 2026.